These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 17386275

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [Abstract] [Full Text] [Related]

  • 3. Ranibizumab and stroke.
    Ueta T, Yanagi Y, Tamaki Y, Yamaguchi T.
    Ophthalmology; 2010 Sep; 117(9):1860; author reply 1860-1. PubMed ID: 20816253
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration.
    Dadgostar H, Ventura AA, Chung JY, Sharma S, Kaiser PK.
    Ophthalmology; 2009 Sep; 116(9):1740-7. PubMed ID: 19643484
    [Abstract] [Full Text] [Related]

  • 8. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L, Ruiz-Moreno JM, Gómez-Ulla F, Fernández M, Montero J.
    Retina; 2009 Sep; 29(10):1444-9. PubMed ID: 19730163
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Dosing regimen and the frequency of macular hemorrhages in neovascular age-related macular degeneration treated with ranibizumab.
    Barbazetto I, Saroj N, Shapiro H, Wong P, Freund KB.
    Retina; 2010 Oct; 30(9):1376-85. PubMed ID: 20683380
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Intravitreal bevacizumab.
    Lucas RS, McKee HD, Lee LR.
    Ophthalmology; 2007 Feb; 114(2):400; author reply 400-1. PubMed ID: 17270701
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Controversies in the treatment of wet age-related macular degeneration.
    Moreno SF, Paloma JB.
    Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.